Big Tech’s recent expansions into medical imaging have business watchers scrambling to decipher the unspoken stratagems beneath the conspicuous moves.

More than half of surveyed radiologists worry about MRI contrast availability, yet almost all—99%—wish for contrast agents that would cut current gadolinium concentrations at least in half.

The meta-analysis included 25 studies and nearly 80,000 patient cases. Experts found that while 94% of those patients with acute atraumatic AMS underwent non-contrast head CT scans, just 11% of those exams yielded positive results. 

“There is a crucial need to develop synthetic vascular graft materials that will increase the rate of long-term functions,” one researcher said. Could materials derived from seaweed help fill that need?

Regardless of whether or not they received reconstructive surgery, post-mastectomy patients probably need no follow-up imaging for breast cancer.

A robust resource is close at hand for military radiologists looking to “transfer” themselves to civilian practice after their service ends.

Getinge has provided a detailed breakdown of the shortage, stating that it is not yet clear when it may be over. The FDA said it will keep a close eye on the situation and provide updates when possible. 

The state of Oregon is taking a hard look at the proposed acquisition of One Medical by Amazon. The deal is valued at $3.9 billion.